targeted therapy

Truong A, Liu J, Ni C, Yashar S. Chilblain lupus erythematosus associated with erdafitinib therapy in a patient with metastatic bladder cancer. JAAD Case Rep.[...]

By sjmartinez • December 10, 2024

Chow F, Lamoureux F, Moriceau G. Editorial: Developing next-generation therapeutics to defeat mutation-driven cancer. Front Immunol. 2024 Sep 26;15:1487952. doi: 10.3389/fimmu.2024.1487952. PMID: 39391312; PMCID: PMC11464455.

By sjmartinez • October 11, 2024

Evans LK, Chen H, Taki Labib M, Cronkite DA, Yu AC, Ashendouek M, Elashoff D, Chai-Ho W, Wong DJ, St John M. Improved Survival of[...]

By sjmartinez • August 21, 2024

Cohen R, Raeisi M, Chibaudel B, Shi Q, Yoshino T, Zalcberg JR, Adams R, Cremolini C, Van Cutsem E, Heinemann V, Tabernero J, Punt CJA,[...]

By sjmartinez • June 20, 2024

Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin[...]

By sjmartinez • June 9, 2024

Stefanoudakis D, Frountzas M, Schizas D, Michalopoulos NV, Drakaki A, Toutouzas KG. Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer. Curr Issues Mol[...]

By sjmartinez • April 27, 2024

Wainberg ZA, Kang YK, Lee KW, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, Teixeira A, Hitre E, Udrea[...]

By sjmartinez • February 4, 2024

Nishino K, Shih JY, Nakagawa K, Reck M, Garon EB, Carlsen M, Matsui T, Visseren-Grul C, Nadal E. RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic[...]

By sjmartinez • February 2, 2024

Lee JM, McNamee CJ, Toloza E, Negrao MV, Lin J, Shum E, Cummings AL, Kris MG, Sepesi B, Bara I, Kurtsikidze N, Schulze K, Ngiam[...]

By sjmartinez • October 27, 2023

Lee JM, McNamee CJ, Toloza E, Negrao MV, Lin J, Shum E, Cummings AL, Kris MG, Sepesi B, Bara I, Kurtsikidze N, Schulze K, Ngiam[...]

By sjmartinez • July 16, 2023